NO323528B1 - 5HT2C reseptormodulatorer, farmasoytiske preparater omfattende disse samt anvendelse derav. - Google Patents
5HT2C reseptormodulatorer, farmasoytiske preparater omfattende disse samt anvendelse derav. Download PDFInfo
- Publication number
- NO323528B1 NO323528B1 NO20044928A NO20044928A NO323528B1 NO 323528 B1 NO323528 B1 NO 323528B1 NO 20044928 A NO20044928 A NO 20044928A NO 20044928 A NO20044928 A NO 20044928A NO 323528 B1 NO323528 B1 NO 323528B1
- Authority
- NO
- Norway
- Prior art keywords
- tetrahydro
- benzazepine
- methyl
- compound according
- methoxy
- Prior art date
Links
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 title description 20
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 title description 18
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 38
- 239000012453 solvate Substances 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims description 225
- 125000000217 alkyl group Chemical group 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 42
- 208000008589 Obesity Diseases 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- 235000020824 obesity Nutrition 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 239000000460 chlorine Substances 0.000 claims description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 27
- 241000124008 Mammalia Species 0.000 claims description 25
- -1 methoxy, ethoxy, n-propoxy, isopropoxy Chemical group 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 235000012631 food intake Nutrition 0.000 claims description 14
- 230000037406 food intake Effects 0.000 claims description 14
- 238000002560 therapeutic procedure Methods 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 238000011321 prophylaxis Methods 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 11
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 9
- YGLDQFWPUCURIP-UHFFFAOYSA-N 3h-3-benzazepine Chemical compound C1=CNC=CC2=CC=CC=C21 YGLDQFWPUCURIP-UHFFFAOYSA-N 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 230000004584 weight gain Effects 0.000 claims description 9
- 235000019786 weight gain Nutrition 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 150000002460 imidazoles Chemical class 0.000 claims description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 235000019627 satiety Nutrition 0.000 claims description 7
- 230000036186 satiety Effects 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- OAJYPPWRJRZVRO-UHFFFAOYSA-N 7-chloro-5-ethyl-8-methoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(OC)=C(Cl)C=C12 OAJYPPWRJRZVRO-UHFFFAOYSA-N 0.000 claims description 4
- SJJIKXOJEDKQRJ-UHFFFAOYSA-N 7-chloro-8-methoxy-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC)C(Cl)=C2 SJJIKXOJEDKQRJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- QSLHEIFNJPYBLS-UHFFFAOYSA-N 7-bromo-5-ethyl-8-methoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(OC)=C(Br)C=C12 QSLHEIFNJPYBLS-UHFFFAOYSA-N 0.000 claims description 3
- TZUDPSHMYVSTRR-UHFFFAOYSA-N 7-bromo-8-methoxy-3,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1CN(C)CC(C)C2=C1C=C(OC)C(Br)=C2 TZUDPSHMYVSTRR-UHFFFAOYSA-N 0.000 claims description 3
- HQQAIJWQKAFMGF-UHFFFAOYSA-N 7-bromo-8-methoxy-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC)C(Br)=C2 HQQAIJWQKAFMGF-UHFFFAOYSA-N 0.000 claims description 3
- DNLSOPHLIKCIIV-UHFFFAOYSA-N 7-chloro-5-ethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(Cl)C=C12 DNLSOPHLIKCIIV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000005336 allyloxy group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- RYYXCFYKJMRFPZ-UHFFFAOYSA-N 5-ethyl-7-iodo-8-methoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(OC)=C(I)C=C12 RYYXCFYKJMRFPZ-UHFFFAOYSA-N 0.000 claims description 2
- IYWYWVMPIJVOBD-UHFFFAOYSA-N 7-bromo-5-methyl-8-prop-2-enoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(OCC=C)=C(Br)C=C12 IYWYWVMPIJVOBD-UHFFFAOYSA-N 0.000 claims description 2
- TXVNTTRQUFIPMP-UHFFFAOYSA-N 7-fluoro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(F)C=C12 TXVNTTRQUFIPMP-UHFFFAOYSA-N 0.000 claims description 2
- MWDDRGPUDJHEAN-UHFFFAOYSA-N 7-iodo-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(I)C=C12 MWDDRGPUDJHEAN-UHFFFAOYSA-N 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 claims 14
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 33
- 208000035475 disorder Diseases 0.000 abstract description 26
- 208000002193 Pain Diseases 0.000 abstract description 11
- 210000003169 central nervous system Anatomy 0.000 abstract description 11
- 230000003542 behavioural effect Effects 0.000 abstract description 10
- 208000020016 psychiatric disease Diseases 0.000 abstract description 9
- 201000001880 Sexual dysfunction Diseases 0.000 abstract description 6
- 206010015037 epilepsy Diseases 0.000 abstract description 6
- 231100000872 sexual dysfunction Toxicity 0.000 abstract description 6
- 208000007848 Alcoholism Diseases 0.000 abstract description 5
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 abstract description 5
- 208000020925 Bipolar disease Diseases 0.000 abstract description 5
- 208000032841 Bulimia Diseases 0.000 abstract description 5
- 206010006550 Bulimia nervosa Diseases 0.000 abstract description 5
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract description 5
- 206010012289 Dementia Diseases 0.000 abstract description 5
- 208000027626 Neurocognitive disease Diseases 0.000 abstract description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract description 5
- 208000028017 Psychotic disease Diseases 0.000 abstract description 5
- 206010041250 Social phobia Diseases 0.000 abstract description 5
- 208000025748 atypical depressive disease Diseases 0.000 abstract description 5
- 206010013663 drug dependence Diseases 0.000 abstract description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract description 5
- 208000022821 personality disease Diseases 0.000 abstract description 5
- 201000000980 schizophrenia Diseases 0.000 abstract description 5
- 208000019116 sleep disease Diseases 0.000 abstract description 5
- 208000011117 substance-related disease Diseases 0.000 abstract description 5
- 206010036618 Premenstrual syndrome Diseases 0.000 abstract description 4
- 201000000484 premenstrual tension Diseases 0.000 abstract description 4
- XTTZERNUQAFMOF-UHFFFAOYSA-N 7-chloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-UHFFFAOYSA-N 0.000 abstract description 3
- 201000009941 intracranial hypertension Diseases 0.000 abstract 1
- 208000020685 sleep-wake disease Diseases 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 216
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 147
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 130
- 239000000203 mixture Substances 0.000 description 122
- 239000000243 solution Substances 0.000 description 109
- 235000019439 ethyl acetate Nutrition 0.000 description 108
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 105
- 239000000047 product Substances 0.000 description 92
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 86
- 239000011734 sodium Substances 0.000 description 75
- 239000003921 oil Substances 0.000 description 67
- 239000012267 brine Substances 0.000 description 66
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
- 239000000377 silicon dioxide Substances 0.000 description 63
- 238000003818 flash chromatography Methods 0.000 description 55
- 238000005481 NMR spectroscopy Methods 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- 239000012074 organic phase Substances 0.000 description 34
- 239000007787 solid Substances 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000012230 colorless oil Substances 0.000 description 21
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000000018 receptor agonist Substances 0.000 description 9
- 229940044601 receptor agonist Drugs 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 6
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 6
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
- VEMUEECVVGWXHA-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(2-iodo-5-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=C(I)C(CCNC(=O)C(F)(F)F)=C1 VEMUEECVVGWXHA-UHFFFAOYSA-N 0.000 description 5
- IIXFGYNBVWNWNL-UHFFFAOYSA-N 7-iodo-8-methoxy-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC)C(I)=C2 IIXFGYNBVWNWNL-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- SFDWWQXMYHWEEN-UHFFFAOYSA-N 2,2,2-trifluoro-n-[1-(2-iodo-5-methoxyphenyl)propan-2-yl]acetamide Chemical compound COC1=CC=C(I)C(CC(C)NC(=O)C(F)(F)F)=C1 SFDWWQXMYHWEEN-UHFFFAOYSA-N 0.000 description 4
- KRBZRTWDEJCQIL-UHFFFAOYSA-N 7-bromo-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(Br)C=C12 KRBZRTWDEJCQIL-UHFFFAOYSA-N 0.000 description 4
- BNEIDDXVFTVOOR-UHFFFAOYSA-N 7-bromo-5-methyl-8-phenylmethoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound BrC=1C=C2C(C)CNCCC2=CC=1OCC1=CC=CC=C1 BNEIDDXVFTVOOR-UHFFFAOYSA-N 0.000 description 4
- 206010022773 Intracranial pressure increased Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 201000010064 diabetes insipidus Diseases 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 201000002859 sleep apnea Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 3
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 3
- FAROVXHASLWCEP-UHFFFAOYSA-N 2,2,2-trifluoro-1-(7-iodo-8-methoxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC(C)C2=C1C=C(OC)C(I)=C2 FAROVXHASLWCEP-UHFFFAOYSA-N 0.000 description 3
- OWLFJDRABVSWMI-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-methoxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC(OC)=CC=C21 OWLFJDRABVSWMI-UHFFFAOYSA-N 0.000 description 3
- SVXNMLSHKBLJPC-UHFFFAOYSA-N 5-methyl-8-(trifluoromethoxy)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(OC(F)(F)F)=CC=C12 SVXNMLSHKBLJPC-UHFFFAOYSA-N 0.000 description 3
- LQGCCOADXMPGTL-UHFFFAOYSA-N 7-bromo-8-ethoxy-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OCC)C(Br)=C2 LQGCCOADXMPGTL-UHFFFAOYSA-N 0.000 description 3
- XHRJDETZSGXGJN-UHFFFAOYSA-N 7-bromo-8-methoxy-2,5-dimethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1C(C)NCC(C)C2=C1C=C(OC)C(Br)=C2 XHRJDETZSGXGJN-UHFFFAOYSA-N 0.000 description 3
- KVGYVFPNKGJTTP-UHFFFAOYSA-N 7-chloro-2,3,4,5-tetrahydro-1h-3-benzazepin-5-ol Chemical compound OC1CNCCC2=CC=C(Cl)C=C12 KVGYVFPNKGJTTP-UHFFFAOYSA-N 0.000 description 3
- YCTGATKQMFYPKK-UHFFFAOYSA-N 8-(2-chlorophenyl)-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=C2C(C)CNCCC2=CC=1C1=CC=CC=C1Cl YCTGATKQMFYPKK-UHFFFAOYSA-N 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- HZAQARMBIAPKGQ-UHFFFAOYSA-N n-[2-(4-chloro-2-iodophenyl)ethyl]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NCCC1=CC=C(Cl)C=C1I HZAQARMBIAPKGQ-UHFFFAOYSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- PIFUPUQFKHPAJN-UHFFFAOYSA-N (7-bromo-8-methoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-5-yl)methanol Chemical compound C1CNCC(CO)C2=C1C=C(OC)C(Br)=C2 PIFUPUQFKHPAJN-UHFFFAOYSA-N 0.000 description 2
- AVMHMVJVHYGDOO-NSCUHMNNSA-N (e)-1-bromobut-2-ene Chemical compound C\C=C\CBr AVMHMVJVHYGDOO-NSCUHMNNSA-N 0.000 description 2
- MOSUXFAHXAGUSY-UHFFFAOYSA-N 1-(5-ethyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CCC1CN(C(=O)C(F)(F)F)CCC2=CC(OC)=CC=C12 MOSUXFAHXAGUSY-UHFFFAOYSA-N 0.000 description 2
- QPUXBSPAUXXABT-UHFFFAOYSA-N 1-(7-bromo-5-methyl-8-phenylmethoxy-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound BrC=1C=C2C(C)CN(C(=O)C(F)(F)F)CCC2=CC=1OCC1=CC=CC=C1 QPUXBSPAUXXABT-UHFFFAOYSA-N 0.000 description 2
- MISHEIKWYPRJAU-UHFFFAOYSA-N 1-(7-bromo-8-ethoxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC(C)C2=C1C=C(OCC)C(Br)=C2 MISHEIKWYPRJAU-UHFFFAOYSA-N 0.000 description 2
- PHJXJYLNHCXKFJ-UHFFFAOYSA-N 1-(7-bromo-8-methoxy-2,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C1C(C)N(C(=O)C(F)(F)F)CC(C)C2=C1C=C(OC)C(Br)=C2 PHJXJYLNHCXKFJ-UHFFFAOYSA-N 0.000 description 2
- MNAUWIZTOWHYGF-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-hydroxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC(O)=CC=C12 MNAUWIZTOWHYGF-UHFFFAOYSA-N 0.000 description 2
- BGWFOEWWYJRPAS-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-methoxy-2,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethanone Chemical compound CC1CN(C(=O)C(F)(F)F)C(C)CC2=CC(OC)=CC=C21 BGWFOEWWYJRPAS-UHFFFAOYSA-N 0.000 description 2
- AKWHNDALUCISMP-UHFFFAOYSA-N 2,2,2-trifluoro-n-[1-(3-methoxyphenyl)propan-2-yl]acetamide Chemical compound COC1=CC=CC(CC(C)NC(=O)C(F)(F)F)=C1 AKWHNDALUCISMP-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- KNWXAUJFZMZHIG-UHFFFAOYSA-N 5-methyl-8-(2-methylpyrazol-3-yl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=C2C(C)CNCCC2=CC=1C1=CC=NN1C KNWXAUJFZMZHIG-UHFFFAOYSA-N 0.000 description 2
- ZPCLKEFGCYRQHH-UHFFFAOYSA-N 5-methyl-8-[3-(trifluoromethyl)phenyl]-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=C2C(C)CNCCC2=CC=1C1=CC=CC(C(F)(F)F)=C1 ZPCLKEFGCYRQHH-UHFFFAOYSA-N 0.000 description 2
- JHQHEPFCSFITQT-UHFFFAOYSA-N 7-bromo-8-methoxy-5-(methoxymethyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound COCC1CNCCC2=CC(OC)=C(Br)C=C12 JHQHEPFCSFITQT-UHFFFAOYSA-N 0.000 description 2
- BPLNPUPEOXRWMZ-UHFFFAOYSA-N 7-chloro-3,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CC1CN(C)CCC2=CC=C(Cl)C=C12 BPLNPUPEOXRWMZ-UHFFFAOYSA-N 0.000 description 2
- FAVBYFITEFEUJI-UHFFFAOYSA-N 7-chloro-5-ethyl-8-fluoro-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(F)=C(Cl)C=C12 FAVBYFITEFEUJI-UHFFFAOYSA-N 0.000 description 2
- OSCDHVCJRHGBTH-UHFFFAOYSA-N 7-chloro-5-methyl-8-prop-2-enoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(OCC=C)=C(Cl)C=C12 OSCDHVCJRHGBTH-UHFFFAOYSA-N 0.000 description 2
- AELPHXGUKIVCSY-UHFFFAOYSA-N 7-chloro-8-fluoro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(F)=C(Cl)C=C12 AELPHXGUKIVCSY-UHFFFAOYSA-N 0.000 description 2
- AADHBPMJORCZGU-UHFFFAOYSA-N 8-(3-methoxyphenyl)-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound COC1=CC=CC(C=2C=C3CCNCC(C)C3=CC=2)=C1 AADHBPMJORCZGU-UHFFFAOYSA-N 0.000 description 2
- DHJBSCDGORFSNH-UHFFFAOYSA-N 8-(4-bromo-2-methylpyrazol-3-yl)-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=C2C(C)CNCCC2=CC=1C1=C(Br)C=NN1C DHJBSCDGORFSNH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 101150013372 Htr2c gene Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000019525 fullness Nutrition 0.000 description 2
- 208000020694 gallbladder disease Diseases 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000005394 methallyl group Chemical group 0.000 description 2
- RVTILUOAJBJUCQ-UHFFFAOYSA-N n-but-2-enyl-2,2,2-trifluoro-n-[2-(2-iodo-5-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=C(I)C(CCN(CC=CC)C(=O)C(F)(F)F)=C1 RVTILUOAJBJUCQ-UHFFFAOYSA-N 0.000 description 2
- CWUJZSYMYSVONE-UHFFFAOYSA-N n-but-2-enyl-n-[2-(4-chloro-2-iodophenyl)ethyl]-2,2,2-trifluoroacetamide Chemical compound CC=CCN(C(=O)C(F)(F)F)CCC1=CC=C(Cl)C=C1I CWUJZSYMYSVONE-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 235000006286 nutrient intake Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 239000008259 solid foam Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229940002552 xenical Drugs 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- JAOGQYKPUONGAZ-UHFFFAOYSA-N 1,3,3-trimethyl-4h-isoquinolin-2-ium;chloride Chemical compound [Cl-].C1=CC=C2C(C)=[NH+]C(C)(C)CC2=C1 JAOGQYKPUONGAZ-UHFFFAOYSA-N 0.000 description 1
- VEJWNIYARKAHFI-UHFFFAOYSA-N 1-(3-methoxyphenyl)propan-2-amine Chemical compound COC1=CC=CC(CC(C)N)=C1 VEJWNIYARKAHFI-UHFFFAOYSA-N 0.000 description 1
- UPLWGKHHFUSAPZ-UHFFFAOYSA-N 1-(5-cyclopropyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C1N(C(=O)C(F)(F)F)CCC2=CC(OC)=CC=C2C1C1CC1 UPLWGKHHFUSAPZ-UHFFFAOYSA-N 0.000 description 1
- DOMUPWJEIUSZAL-UHFFFAOYSA-N 1-(7-bromo-5-cyclopropyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C1=2C=C(Br)C(OC)=CC=2CCN(C(=O)C(F)(F)F)CC1C1CC1 DOMUPWJEIUSZAL-UHFFFAOYSA-N 0.000 description 1
- AQOSFQSZCQOSAL-UHFFFAOYSA-N 1-(7-bromo-8-hydroxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC(O)=C(Br)C=C12 AQOSFQSZCQOSAL-UHFFFAOYSA-N 0.000 description 1
- CZWLLKUQTSVTEG-UHFFFAOYSA-N 1-(7-bromo-8-hydroxy-5-propan-2-yl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CC(C)C1CN(C(=O)C(F)(F)F)CCC2=CC(O)=C(Br)C=C12 CZWLLKUQTSVTEG-UHFFFAOYSA-N 0.000 description 1
- IQAYUEBXKJEXFL-UHFFFAOYSA-N 1-(7-bromo-8-methoxy-5-propan-2-yl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC(C(C)C)C2=C1C=C(OC)C(Br)=C2 IQAYUEBXKJEXFL-UHFFFAOYSA-N 0.000 description 1
- IDRPHZLQNLNHCT-UHFFFAOYSA-N 1-(7-chloro-5-ethyl-8-methoxy-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CCC1CN(C(=O)C(F)(F)F)CCC2=CC(OC)=C(Cl)C=C12 IDRPHZLQNLNHCT-UHFFFAOYSA-N 0.000 description 1
- UXBDPZUGINVRNA-UHFFFAOYSA-N 1-(7-chloro-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC=C(Cl)C=C12 UXBDPZUGINVRNA-UHFFFAOYSA-N 0.000 description 1
- BWWIMWNIOJOJKB-UHFFFAOYSA-N 1-(7-chloro-5-methylidene-2,4-dihydro-1h-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound C=C1CN(C(=O)C(F)(F)F)CCC2=CC=C(Cl)C=C21 BWWIMWNIOJOJKB-UHFFFAOYSA-N 0.000 description 1
- BJADFICBTPMQQP-UHFFFAOYSA-N 1-(7-chloro-8-fluoro-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC(F)=C(Cl)C=C12 BJADFICBTPMQQP-UHFFFAOYSA-N 0.000 description 1
- OJZXNHRNWZXDQK-UHFFFAOYSA-N 1-(7-chloro-8-hydroxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)-2,2,2-trifluoroethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC(O)=C(Cl)C=C12 OJZXNHRNWZXDQK-UHFFFAOYSA-N 0.000 description 1
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- DCTWSFKSTLWEQH-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-hydroxy-7-iodo-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethanone Chemical compound CC1CN(C(=O)C(F)(F)F)CCC2=CC(O)=C(I)C=C12 DCTWSFKSTLWEQH-UHFFFAOYSA-N 0.000 description 1
- CFWJLHUKYHXFBZ-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-methoxy-2-methyl-5-methylidene-2,4-dihydro-1h-3-benzazepin-3-yl)ethanone Chemical compound C1C(C)N(C(=O)C(F)(F)F)CC(=C)C=2C1=CC(OC)=CC=2 CFWJLHUKYHXFBZ-UHFFFAOYSA-N 0.000 description 1
- GIVVAVSOCDSEPD-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-methoxy-5-methylidene-2,4-dihydro-1h-3-benzazepin-3-yl)ethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC(=C)C=2C1=CC(OC)=CC=2 GIVVAVSOCDSEPD-UHFFFAOYSA-N 0.000 description 1
- SODRYPVLRPDKBP-UHFFFAOYSA-N 2,2,2-trifluoro-1-(8-methoxy-5-propan-2-yl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)ethanone Chemical compound CC(C)C1CN(C(=O)C(F)(F)F)CCC2=CC(OC)=CC=C21 SODRYPVLRPDKBP-UHFFFAOYSA-N 0.000 description 1
- FYEGBRIXPRSPFL-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(2-iodo-5-methoxyphenyl)ethyl]-n-(3-methylbut-2-enyl)acetamide Chemical compound COC1=CC=C(I)C(CCN(CC=C(C)C)C(=O)C(F)(F)F)=C1 FYEGBRIXPRSPFL-UHFFFAOYSA-N 0.000 description 1
- JHEXQQMMXISZMO-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(3-methoxyphenyl)ethyl]acetamide Chemical compound COC1=CC=CC(CCNC(=O)C(F)(F)F)=C1 JHEXQQMMXISZMO-UHFFFAOYSA-N 0.000 description 1
- MWVMYAWMFTVYED-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC=CC=C21 MWVMYAWMFTVYED-UHFFFAOYSA-N 0.000 description 1
- MQPUAVYKVIHUJP-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C(Cl)=C1 MQPUAVYKVIHUJP-UHFFFAOYSA-N 0.000 description 1
- NRHVNPYOTNGECT-UHFFFAOYSA-N 2-(3-chlorophenyl)ethanamine Chemical compound NCCC1=CC=CC(Cl)=C1 NRHVNPYOTNGECT-UHFFFAOYSA-N 0.000 description 1
- AUCVZEYHEFAWHO-UHFFFAOYSA-N 2-(3-fluorophenyl)ethanamine Chemical compound NCCC1=CC=CC(F)=C1 AUCVZEYHEFAWHO-UHFFFAOYSA-N 0.000 description 1
- WJBMRZAHTUFBGE-UHFFFAOYSA-N 2-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC(CCN)=C1 WJBMRZAHTUFBGE-UHFFFAOYSA-N 0.000 description 1
- ZSZCXAOQVBEPME-UHFFFAOYSA-N 2-(4-bromophenyl)ethanamine Chemical compound NCCC1=CC=C(Br)C=C1 ZSZCXAOQVBEPME-UHFFFAOYSA-N 0.000 description 1
- SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 1
- CKLFJWXRWIQYOC-UHFFFAOYSA-N 2-(4-fluorophenyl)ethanamine Chemical compound NCCC1=CC=C(F)C=C1 CKLFJWXRWIQYOC-UHFFFAOYSA-N 0.000 description 1
- XOPVABPXMZJUBF-UHFFFAOYSA-N 2-[3-(trifluoromethoxy)phenyl]ethanamine Chemical compound NCCC1=CC=CC(OC(F)(F)F)=C1 XOPVABPXMZJUBF-UHFFFAOYSA-N 0.000 description 1
- HMFOBPNVAAAACP-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound NCCC1=CC=C(C(F)(F)F)C=C1 HMFOBPNVAAAACP-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- MYWAFGWFCUWUAA-UHFFFAOYSA-N 3,3,3-trifluoro-1-(7-iodo-8-methoxy-5-methyl-1,2,4,5-tetrahydro-3-benzazepin-3-yl)propan-1-one Chemical compound C1CN(C(=O)CC(F)(F)F)CC(C)C2=C1C=C(OC)C(I)=C2 MYWAFGWFCUWUAA-UHFFFAOYSA-N 0.000 description 1
- LGUJJJJNBBUBHT-UHFFFAOYSA-N 5-ethyl-7-iodo-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(I)C=C12 LGUJJJJNBBUBHT-UHFFFAOYSA-N 0.000 description 1
- LQTVRHJWZUURQS-UHFFFAOYSA-N 5-ethyl-7-iodo-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CCC1CN(C)CCC2=CC=C(I)C=C12 LQTVRHJWZUURQS-UHFFFAOYSA-N 0.000 description 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
- GBYLNYMTYZRQLE-UHFFFAOYSA-N 5-methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC=C(C(F)(F)F)C=C12 GBYLNYMTYZRQLE-UHFFFAOYSA-N 0.000 description 1
- FIODSXIEFAJLSL-UHFFFAOYSA-N 5-methyl-8-[2-(trifluoromethyl)phenyl]-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C=1C=C2C(C)CNCCC2=CC=1C1=CC=CC=C1C(F)(F)F FIODSXIEFAJLSL-UHFFFAOYSA-N 0.000 description 1
- MHKBBXMJDQZGEO-UHFFFAOYSA-N 7,8-dichloro-3,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CC1CN(C)CCC2=CC(Cl)=C(Cl)C=C12 MHKBBXMJDQZGEO-UHFFFAOYSA-N 0.000 description 1
- TTXLZSFANXGSGY-UHFFFAOYSA-N 7,8-dichloro-5-ethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC(Cl)=C(Cl)C=C12 TTXLZSFANXGSGY-UHFFFAOYSA-N 0.000 description 1
- KTCVEIAEKPSBCJ-UHFFFAOYSA-N 7,8-dichloro-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1CNCCC2=CC(Cl)=C(Cl)C=C12 KTCVEIAEKPSBCJ-UHFFFAOYSA-N 0.000 description 1
- ZVWYXVHPZNQTGP-UHFFFAOYSA-N 7-(2-chlorophenyl)-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1=C2C(C)CNCCC2=CC=C1C1=CC=CC=C1Cl ZVWYXVHPZNQTGP-UHFFFAOYSA-N 0.000 description 1
- DJXILNIIDWIGHS-UHFFFAOYSA-N 7-bromo-3,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CC1CN(C)CCC2=CC=C(Br)C=C12 DJXILNIIDWIGHS-UHFFFAOYSA-N 0.000 description 1
- CJNIKSUHKLMLAY-UHFFFAOYSA-N 7-bromo-5-cyclopropyl-8-methoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1=2C=C(Br)C(OC)=CC=2CCNCC1C1CC1 CJNIKSUHKLMLAY-UHFFFAOYSA-N 0.000 description 1
- FZAXXXCRTZYHAH-UHFFFAOYSA-N 7-bromo-5-ethyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CCC1CNCCC2=CC=C(Br)C=C12 FZAXXXCRTZYHAH-UHFFFAOYSA-N 0.000 description 1
- ULXCAHWFUIUQEW-UHFFFAOYSA-N 7-bromo-5-ethyl-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CCC1CN(C)CCC2=CC=C(Br)C=C12 ULXCAHWFUIUQEW-UHFFFAOYSA-N 0.000 description 1
- RDULHDNEXHNBOM-UHFFFAOYSA-N 7-bromo-5-ethyl-8-methoxy-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CCC1CN(C)CCC2=CC(OC)=C(Br)C=C12 RDULHDNEXHNBOM-UHFFFAOYSA-N 0.000 description 1
- UWFSZQMKPCCKFT-UHFFFAOYSA-N 7-bromo-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepin-8-ol Chemical compound CC1CNCCC2=CC(O)=C(Br)C=C12 UWFSZQMKPCCKFT-UHFFFAOYSA-N 0.000 description 1
- OKANWZMGTYYNOW-UHFFFAOYSA-N 7-bromo-5-methyl-8-propan-2-yloxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC(C)C)C(Br)=C2 OKANWZMGTYYNOW-UHFFFAOYSA-N 0.000 description 1
- YJMJIRPWYQUXFC-UHFFFAOYSA-N 7-bromo-5-propan-2-yl-2,3,4,5-tetrahydro-1h-3-benzazepin-8-ol Chemical compound CC(C)C1CNCCC2=CC(O)=C(Br)C=C12 YJMJIRPWYQUXFC-UHFFFAOYSA-N 0.000 description 1
- CABPILKLTHGNHC-UHFFFAOYSA-N 7-bromo-5-propan-2-yl-8-prop-2-enoxy-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC(C)C1CNCCC2=CC(OCC=C)=C(Br)C=C12 CABPILKLTHGNHC-UHFFFAOYSA-N 0.000 description 1
- IHRBUEKNYVJQIC-UHFFFAOYSA-N 7-bromo-8-methoxy-5-propan-2-yl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C(C)C)C2=C1C=C(OC)C(Br)=C2 IHRBUEKNYVJQIC-UHFFFAOYSA-N 0.000 description 1
- VYQCTJXELAKSPO-UHFFFAOYSA-N 7-chloro-3-(2,2,2-trifluoroacetyl)-2,4-dihydro-1h-3-benzazepin-5-one Chemical compound O=C1CN(C(=O)C(F)(F)F)CCC2=CC=C(Cl)C=C21 VYQCTJXELAKSPO-UHFFFAOYSA-N 0.000 description 1
- AWRJKSXXJCTQGQ-UHFFFAOYSA-N 7-chloro-5-ethyl-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CCC1CN(C)CCC2=CC=C(Cl)C=C12 AWRJKSXXJCTQGQ-UHFFFAOYSA-N 0.000 description 1
- GCMZECZBLQENBZ-UHFFFAOYSA-N 7-chloro-5-ethyl-8-fluoro-3-methyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CCC1CN(C)CCC2=CC(F)=C(Cl)C=C12 GCMZECZBLQENBZ-UHFFFAOYSA-N 0.000 description 1
- CKXNNAQKSQRYNX-UHFFFAOYSA-N 7-chloro-8-(2-fluorophenyl)-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound ClC=1C=C2C(C)CNCCC2=CC=1C1=CC=CC=C1F CKXNNAQKSQRYNX-UHFFFAOYSA-N 0.000 description 1
- KXTAUGYNHFAGFL-UHFFFAOYSA-N 7-iodo-8-methoxy-3,5-dimethyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1CN(C)CC(C)C2=C1C=C(OC)C(I)=C2 KXTAUGYNHFAGFL-UHFFFAOYSA-N 0.000 description 1
- RRUVWNUSSPWKJJ-UHFFFAOYSA-N 7-iodo-8-methoxy-5-methyl-3-propyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound CC1CN(CCC)CCC2=CC(OC)=C(I)C=C21 RRUVWNUSSPWKJJ-UHFFFAOYSA-N 0.000 description 1
- HXIGMEDVVRGQPH-UHFFFAOYSA-N 8-methoxy-5-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine-7-carbonitrile Chemical compound C1CNCC(C)C2=C1C=C(OC)C(C#N)=C2 HXIGMEDVVRGQPH-UHFFFAOYSA-N 0.000 description 1
- WBGUZBYKIJAQIY-UHFFFAOYSA-N 8-methoxy-5-methyl-7-(1,1,2,2,2-pentafluoroethyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC)C(C(F)(F)C(F)(F)F)=C2 WBGUZBYKIJAQIY-UHFFFAOYSA-N 0.000 description 1
- VZPBGKYNLKOIBH-UHFFFAOYSA-N 8-methoxy-5-methyl-7-(trifluoromethyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCC(C)C2=C1C=C(OC)C(C(F)(F)F)=C2 VZPBGKYNLKOIBH-UHFFFAOYSA-N 0.000 description 1
- BOQDOEZEZODMKK-UHFFFAOYSA-N 8-methoxy-5-methyl-7-thiophen-2-yl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound COC1=CC=2CCNCC(C)C=2C=C1C1=CC=CS1 BOQDOEZEZODMKK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 101100113507 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cnh-1 gene Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000002426 anti-panic effect Effects 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000045993 human HTR2C Human genes 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical compound [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- HHWWCQUOZKIFSQ-UHFFFAOYSA-N n-[2-(4-chloro-2-iodophenyl)ethyl]-2,2,2-trifluoro-n-prop-2-enylacetamide Chemical compound FC(F)(F)C(=O)N(CC=C)CCC1=CC=C(Cl)C=C1I HHWWCQUOZKIFSQ-UHFFFAOYSA-N 0.000 description 1
- WYDGTGQCBWGKJN-UHFFFAOYSA-N n-[2-(4-chlorophenyl)ethyl]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)NCCC1=CC=C(Cl)C=C1 WYDGTGQCBWGKJN-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- UYCAUPASBSROMS-AWQJXPNKSA-M sodium;2,2,2-trifluoroacetate Chemical compound [Na+].[O-][13C](=O)[13C](F)(F)F UYCAUPASBSROMS-AWQJXPNKSA-M 0.000 description 1
- SCWLIHXXYXFUFV-UHFFFAOYSA-M sodium;2,2,3,3,3-pentafluoropropanoate Chemical compound [Na+].[O-]C(=O)C(F)(F)C(F)(F)F SCWLIHXXYXFUFV-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006441 vascular event Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37205802P | 2002-04-12 | 2002-04-12 | |
| US40549502P | 2002-08-23 | 2002-08-23 | |
| US43460702P | 2002-12-18 | 2002-12-18 | |
| US10/410,991 US6953787B2 (en) | 2002-04-12 | 2003-04-10 | 5HT2C receptor modulators |
| PCT/US2003/011076 WO2003086306A2 (en) | 2002-04-12 | 2003-04-11 | 5ht2c receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20044928L NO20044928L (no) | 2004-12-13 |
| NO323528B1 true NO323528B1 (no) | 2007-06-04 |
Family
ID=29255581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20044928A NO323528B1 (no) | 2002-04-12 | 2004-11-11 | 5HT2C reseptormodulatorer, farmasoytiske preparater omfattende disse samt anvendelse derav. |
Country Status (28)
| Country | Link |
|---|---|
| US (11) | US6953787B2 (enExample) |
| EP (4) | EP1557409A1 (enExample) |
| JP (5) | JP4155926B2 (enExample) |
| KR (3) | KR100908166B1 (enExample) |
| CN (5) | CN100486967C (enExample) |
| AT (1) | ATE294781T1 (enExample) |
| AU (1) | AU2003221866B2 (enExample) |
| BR (2) | BR122017023795B8 (enExample) |
| CA (1) | CA2481723C (enExample) |
| CR (2) | CR7503A (enExample) |
| DE (1) | DE60300610T2 (enExample) |
| DK (1) | DK1411881T3 (enExample) |
| ES (2) | ES2242165T3 (enExample) |
| GE (1) | GEP20074197B (enExample) |
| IL (1) | IL164162A0 (enExample) |
| IS (1) | IS2134B (enExample) |
| MX (1) | MXPA04009965A (enExample) |
| MY (1) | MY141476A (enExample) |
| NO (1) | NO323528B1 (enExample) |
| NZ (1) | NZ535381A (enExample) |
| PL (4) | PL211314B1 (enExample) |
| PT (1) | PT1411881E (enExample) |
| RU (1) | RU2317982C2 (enExample) |
| SI (1) | SI1411881T1 (enExample) |
| TW (1) | TWI252105B (enExample) |
| UA (1) | UA77788C2 (enExample) |
| WO (1) | WO2003086306A2 (enExample) |
| ZA (1) | ZA200408506B (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8478824B2 (en) * | 2002-02-05 | 2013-07-02 | Portauthority Technologies Inc. | Apparatus and method for controlling unauthorized dissemination of electronic mail |
| SE0200968D0 (sv) * | 2002-03-26 | 2002-03-26 | Lars Baltzer | Novel polypeptide scaffolds and use thereof |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| PL220722B1 (pl) | 2002-12-20 | 2015-12-31 | Glaxo Group Ltd | Benzoazepinowe pochodne, zawierająca je kompozycja farmaceutyczna i ich zastosowania do wytwarzania leku i do leczenia chorób neurologicznych |
| EP2332921B1 (en) * | 2003-06-17 | 2016-03-02 | Arena Pharmaceuticals, Inc. | 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride |
| CA2888392A1 (en) * | 2003-06-17 | 2005-03-03 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
| TW200510324A (en) * | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US20070275949A1 (en) * | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
| MXPA06004307A (es) * | 2003-10-23 | 2006-06-05 | Hoffmann La Roche | Derivados de benzazepina como inhibidores de mao-b. |
| CN1934088A (zh) | 2004-02-25 | 2007-03-21 | 伊莱利利公司 | 作为5－HT<sub>2c</sub>受体激动剂的6－取代的2,3,4,5－四氢－1H－苯并[d]氮杂䓬 |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| DE602005027861D1 (de) * | 2004-09-03 | 2011-06-16 | Athersys Inc | Trizyklische heteroaryl-piperazine, pyrrolidine und azetidine als serotonin-rezeptor-modulatoren |
| US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| WO2006044762A2 (en) * | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor |
| WO2006065686A2 (en) * | 2004-12-13 | 2006-06-22 | Galileo Pharmaceuticals, Inc. | Spiro derivatives as lipoxygenase inhibitors |
| EA201200954A1 (ru) * | 2004-12-21 | 2013-05-30 | Арена Фармасьютикалз, Инк. | Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение |
| RS50997B (sr) | 2004-12-23 | 2010-10-31 | Arena Pharmaceuticals Inc. | Kompozicije 5ht2c receptor modulatora i postupci njihove upotrebe |
| AU2012201515B2 (en) * | 2004-12-23 | 2015-01-29 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulator compositions and methods of use |
| NZ560917A (en) * | 2005-03-31 | 2011-01-28 | Pfizer Prod Inc | Cyclopentapyridine and tetrahydroquinoline derivatives |
| US20090203750A1 (en) * | 2005-08-24 | 2009-08-13 | Alan Kozikowski | 5-HT2C Receptor Agonists as Anorectic Agents |
| CA2619287C (en) * | 2005-09-01 | 2013-10-22 | Eli Lilly And Company | 6-substituted 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| PT1924561E (pt) | 2005-09-01 | 2013-01-16 | Lilly Co Eli | Módulo de cabeça de impressão tendo uma fiada solta e controlador de impressora para lhe fornecer dados |
| ES2440483T3 (es) * | 2005-09-01 | 2014-01-29 | Eli Lilly And Company | 2,3,4,5-Tetrahidro-1H-benzo[d]azepinas sustituidas con heterociclo enlazado en 6-N como agonistas del receptor 5-HT2C |
| DE602006008323D1 (de) * | 2005-09-01 | 2009-09-17 | Lilly Co Eli | 6-substituierte- 2,3,4,5-tetrahydro-1h-benzoädüazepine als 5-ht2c-rezeptoragonisten |
| DE102006009004A1 (de) * | 2006-02-23 | 2007-09-06 | Sustech Gmbh & Co. Kg | Multifunktionelle sternförmige Präpolymere, deren Herstellung und Verwendung |
| EP2001852A2 (en) | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| US7897595B2 (en) * | 2006-05-26 | 2011-03-01 | Forest Laboratories Holdings Limited | Pyridoazepine derivatives |
| WO2007149728A2 (en) * | 2006-06-20 | 2007-12-27 | Alcon Research, Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| MX2009000508A (es) * | 2006-07-14 | 2009-01-27 | Pfizer Prod Inc | Sal tartrato de (7s)-7-[(5-fluoro-2-metil-bencil)oxi]-2-[(2r)-2-me tilpiperazin-1-il]-6,7-dihidro-5h-ciclopenta[b]piridina. |
| JP5404414B2 (ja) * | 2006-12-05 | 2014-01-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンおよびその中間体を調製するための方法 |
| CA2671984A1 (en) * | 2006-12-11 | 2008-06-19 | Boehringer Ingelheim International Gmbh | New pyridazine derivatives with mch antagonistic activity and medicaments comprising these compounds |
| WO2009051747A1 (en) * | 2007-10-15 | 2009-04-23 | Concert Pharmaceuticals, Inc. | Deuterated lorcaserin |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| US8822727B2 (en) * | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| CA2719721C (en) | 2008-03-26 | 2012-12-18 | Daiichi Sankyo Company, Limited | Tetrahydroisoquinoline derivative |
| EP2246331A1 (en) * | 2009-04-24 | 2010-11-03 | Westfälische Wilhelms-Universität Münster | NR2B-selective NMDA-receptor antagonists |
| EP2443080A2 (en) | 2009-06-18 | 2012-04-25 | Arena Pharmaceuticals, Inc. | Process for the preparation of 5-ht2c receptor agonists |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| AU2011212930B2 (en) | 2010-02-04 | 2016-02-11 | The Board Of Trustees Of The University Of Illinois | Highly selective 5-HT(2C) receptor agonists having antagonist activity at the 5-HT(2B) receptor |
| WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
| BR112012021231A2 (pt) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto |
| US20110269744A1 (en) | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| JP6054861B2 (ja) | 2010-03-26 | 2016-12-27 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| US9045431B2 (en) | 2010-06-02 | 2015-06-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 5-HT2C receptor agonists |
| MX2013002430A (es) * | 2010-09-01 | 2013-07-22 | Arena Pharm Inc | Formas de dosis de disolucion de rápida de agonistas de 5-ht2c. |
| CN103189053A (zh) | 2010-09-01 | 2013-07-03 | 艾尼纳制药公司 | 用于体重控制的5-ht2c激动剂的调节释放剂型 |
| JP2013539470A (ja) * | 2010-09-01 | 2013-10-24 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ロルカセリンと光学活性な酸との塩 |
| SG10201506865WA (en) * | 2010-09-01 | 2015-10-29 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| AU2011296015B2 (en) | 2010-09-01 | 2015-11-12 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| AU2012311484B2 (en) | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
| CN102895233B (zh) * | 2012-09-04 | 2015-06-24 | 苏州大学 | 苯并氮杂卓类化合物在制备预防或治疗癫痫的药物中的应用 |
| UY34436A (es) | 2012-10-09 | 2014-07-31 | Arena Pharm Inc | Metodo de control del peso |
| WO2014060575A2 (en) | 2012-10-19 | 2014-04-24 | Medichem S.A. | Process for the enantioselective synthesis of a tetrahydrobenzazepine compound |
| KR20160021758A (ko) | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트 |
| WO2014187768A1 (en) | 2013-05-20 | 2014-11-27 | Lek Pharmaceuticals D.D. | Novel synthetic processes to 8-chloro-3-benzo[d]azepine via friedel-crafts alkylation of olefin |
| EP3010887A1 (en) | 2013-06-21 | 2016-04-27 | LEK Pharmaceuticals d.d. | Preparation of chiral 1-methyl-2,3,4,5-1h-benzodiazepines via asymmetric reduction of alpha-substituted styrenes |
| EP3022183A1 (en) * | 2013-07-19 | 2016-05-25 | LEK Pharmaceuticals d.d. | Method of racemisation of undesired enantiomers |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| EP2868656A1 (en) | 2013-11-05 | 2015-05-06 | LEK Pharmaceuticals d.d. | Stabilized amorphous lorcaserin hydrochloride |
| CN104936947B (zh) * | 2013-12-27 | 2017-03-08 | 杭州普晒医药科技有限公司 | 氯卡色林盐及其晶体、其制备方法和用途 |
| US9981912B2 (en) | 2014-04-21 | 2018-05-29 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof |
| WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
| WO2016069875A1 (en) | 2014-10-30 | 2016-05-06 | Arena Pharmaceuticals, Inc. | Compositions and methods for ceasing tobacco smoking |
| US10407381B2 (en) | 2015-01-29 | 2019-09-10 | The Board Of Trustees Of The University Of Illinois | Cyclopropylmethanamines as selective 5-HT(2C) receptor agonists |
| KR20180031035A (ko) * | 2015-07-31 | 2018-03-27 | 아레나 파마슈티칼스, 인크. | 5-ht2c 수용체 효능제 및 조성물 및 사용 방법 |
| DE102015117882A1 (de) * | 2015-10-21 | 2017-04-27 | Mehrdad Ghashghaeinia | Pharmazeutische Zusammensetzung |
| EP3210975A1 (en) | 2016-02-24 | 2017-08-30 | Enantia, S.L. | Cocrystals of lorcaserin |
| JP6725838B2 (ja) * | 2016-09-16 | 2020-07-22 | 富士通クライアントコンピューティング株式会社 | ヒンジ、スタンド装置、及び、電子機器 |
| EP3596107A1 (en) | 2017-03-15 | 2020-01-22 | Novo Nordisk A/S | Bicyclic compounds capable of binding to melanocortin 4 receptor |
| SG11201908131RA (en) | 2017-03-15 | 2019-10-30 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| WO2019219714A1 (en) | 2018-05-15 | 2019-11-21 | Novo Nordisk A/S | Compounds capable of binding to melanocortin 4 receptor |
| KR20190132711A (ko) | 2018-05-21 | 2019-11-29 | 주식회사 다림바이오텍 | 비만 예방 또는 치료용 약학 조성물 |
| KR20190133482A (ko) | 2018-05-23 | 2019-12-03 | 동국제약 주식회사 | 흰강낭콩 및 아위버섯 추출물을 함유하는 항비만 또는 체지방 감소용 조성물 |
| WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
| WO2025252661A1 (en) | 2024-06-03 | 2025-12-11 | Immunic Ag | Reducing body weight and/or induction of satiety by triazolo compounds |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US434607A (en) | 1890-08-19 | Barrel-washing machine | ||
| US372058A (en) | 1887-10-25 | William m | ||
| US405495A (en) | 1889-06-18 | Picker-staff connection for looms | ||
| CH498122A (de) | 1968-02-09 | 1970-10-31 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates |
| CH481110A (de) | 1967-02-17 | 1969-11-15 | Geigy Ag J R | Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen |
| CH500194A (de) | 1968-02-15 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Tetrahydroazepinderivaten |
| GB1268243A (en) | 1968-03-11 | 1972-03-22 | Wallace & Tiernan Inc | 0,2,4,5,-tetrahydro-3h,3-benzazepines |
| US4233217A (en) | 1968-03-11 | 1980-11-11 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines |
| FR7736M (enExample) | 1968-09-02 | 1970-03-09 | ||
| US3592523A (en) * | 1969-05-19 | 1971-07-13 | Ncr Co | Angle multiplier apparatus |
| US3716639A (en) | 1970-03-11 | 1973-02-13 | Ciba Geigy Corp | Anorexigenic tetrahydrobenzazepines |
| US3795683A (en) | 1970-08-19 | 1974-03-05 | Hoffmann La Roche | 2,3,4,5-tetrahydro-1h-3-benzazepines |
| LU65954A1 (enExample) * | 1972-08-25 | 1974-03-07 | ||
| US4210749A (en) * | 1974-11-12 | 1980-07-01 | Pennwalt Corporation | Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines |
| US4111957A (en) | 1977-02-02 | 1978-09-05 | Smithkline Corporation | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| US4108989A (en) | 1977-04-01 | 1978-08-22 | Smithkline Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones |
| CA1090797A (en) | 1978-06-20 | 1980-12-02 | Kenneth G. Holden | Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1h- 3-benzazepine compounds |
| AU515236B2 (en) | 1978-06-26 | 1981-03-26 | Smithkline Corporation | Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives |
| ZA792785B (en) | 1978-07-07 | 1980-08-27 | Smithkline Corp | Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines |
| EP0161350A1 (en) | 1981-11-27 | 1985-11-21 | Smithkline Beckman Corporation | Process for preparing benzazepines |
| FR2525603A1 (fr) | 1982-04-27 | 1983-10-28 | Adir | Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique |
| US4988690A (en) | 1982-06-14 | 1991-01-29 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof |
| US4541954A (en) | 1984-09-05 | 1985-09-17 | Smithkline Beckman Corporation | Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US4762845A (en) | 1986-05-21 | 1988-08-09 | Abbott Laboratories | 7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids |
| EP0285287A3 (en) | 1987-03-23 | 1990-08-16 | Smithkline Beecham Corporation | 3-benzazepine compounds for use in treating gastrointestinal motility disorders |
| US5247080A (en) * | 1987-03-27 | 1993-09-21 | Schering Corporation | Substituted benzazepines useful as intermediates for producing pharmaceutically active compounds |
| ZA882080B (en) | 1987-03-27 | 1989-04-26 | Schering Corp | Substituted benzazepines,their preparation and pharmaceutical compositions containing them |
| US5015639A (en) * | 1987-03-27 | 1991-05-14 | Schering Corporation | Substituted benzazepines, their preparation and pharmaceutical compositions containing them |
| AU1700688A (en) | 1987-04-09 | 1988-11-04 | Smithkline Beckman Corporation | Sulfinyl and sulfonyl substituted 3-benzazepines |
| US5105639A (en) * | 1989-02-23 | 1992-04-21 | Spiro America Inc. | Apparatus for forming spiral pipe |
| US5422355A (en) * | 1989-06-02 | 1995-06-06 | John Wyeth & Brother, Limited | Composition for treating depression with (N-heteroaryl)alkylamines |
| US5178786A (en) * | 1989-08-04 | 1993-01-12 | The Lubrizol Corporation | Corrosion-inhibiting compositions and functional fluids containing same |
| AU8201591A (en) | 1990-06-15 | 1992-01-07 | Schering Corporation | 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them |
| US5275915A (en) * | 1991-06-05 | 1994-01-04 | Dainippon Ink And Chemicals, Inc. | Developer for light-sensitive material |
| AU1927992A (en) | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Medicaments |
| EP0558824A1 (en) * | 1992-02-04 | 1993-09-08 | Duphar International Research B.V | Method for the preparation of vicinal aminoalcohols and optically active O-protected derivatives thereof |
| JPH05339263A (ja) | 1992-06-08 | 1993-12-21 | Wakunaga Pharmaceut Co Ltd | ジヒドロピリジン誘導体 |
| JPH06298746A (ja) | 1993-04-19 | 1994-10-25 | Showa Denko Kk | 環状イミド酸エステルの製造法 |
| WO1995000131A1 (en) * | 1993-06-23 | 1995-01-05 | Cambridge Neuroscience, Incorporated | Sigma receptor ligands and the use thereof |
| US5387685A (en) * | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| GB9322976D0 (en) | 1993-11-08 | 1994-01-05 | Pfizer Ltd | Therapeutic agents |
| DE4419315A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419246A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie |
| DE4419247A1 (de) * | 1994-06-01 | 1995-12-07 | Merckle Gmbh | Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie |
| DE4427838A1 (de) | 1994-08-05 | 1996-02-08 | Thomae Gmbh Dr K | Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE4429079A1 (de) | 1994-08-17 | 1996-02-22 | Thomae Gmbh Dr K | Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JPH08134048A (ja) | 1994-11-08 | 1996-05-28 | Sumitomo Chem Co Ltd | オキサゾリン類の製造法 |
| DE19510566A1 (de) * | 1995-03-23 | 1996-09-26 | Kali Chemie Pharma Gmbh | Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| GB9508622D0 (en) | 1995-04-28 | 1995-06-14 | Pfizer Ltd | Therapeutic agants |
| US5958543A (en) | 1995-07-07 | 1999-09-28 | Stor Media,Inc. | Micro-texturing for sputtered, thin film magnetic media disks utilizing titanium sputtered in the presence of hydrogen to form micro-texturing |
| JPH0930960A (ja) | 1995-07-18 | 1997-02-04 | Takasago Internatl Corp | 真菌感染症治療剤 |
| JPH0987258A (ja) | 1995-09-28 | 1997-03-31 | Sumitomo Chem Co Ltd | オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法 |
| CA2190708A1 (en) | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
| US5892116A (en) | 1996-01-03 | 1999-04-06 | Georgetown University | Gelators |
| US5925651A (en) * | 1996-04-03 | 1999-07-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| EP0920417A4 (en) | 1996-08-15 | 1999-12-29 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| JP2001514631A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | ４，５，６，７−テトラヒドロ−チエノ［３，２−ｃ］ピリジン誘導体類、それらの製造方法及び使用 |
| AUPP020297A0 (en) | 1997-11-05 | 1997-11-27 | University Of Melbourne, The | A novel receptor, and compounds which bind thereto |
| EP0987235B1 (en) | 1998-08-25 | 2003-03-12 | MERCK PATENT GmbH | Method for the conversion of arenes or alkenes with iodoalkenes, aryl iodides or arenediazonium salts |
| ATE254614T1 (de) * | 1999-08-06 | 2003-12-15 | Hoffmann La Roche | Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten |
| EP1074549B1 (en) | 1999-08-06 | 2003-11-19 | F. Hoffmann-La Roche Ag | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors |
| DE10003708A1 (de) * | 2000-01-28 | 2001-08-02 | Solvent Innovation Gmbh | Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form |
| ATE382617T1 (de) | 2000-11-14 | 2008-01-15 | Smithkline Beecham Plc | Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| JPWO2002074746A1 (ja) | 2001-03-16 | 2004-07-08 | 山之内製薬株式会社 | ベンゾアゼピン誘導体 |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| BR0212787A (pt) | 2001-09-24 | 2005-01-25 | Elan Pharm Inc | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica |
| AU2003214873A1 (en) | 2002-01-18 | 2003-09-02 | Ceretek Llc | Methods of treating conditions associated with an edg receptor |
| DE60334787D1 (de) * | 2002-03-12 | 2010-12-16 | Merck Sharp & Dohme | Substituierte amide |
| US6953787B2 (en) * | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| EP2332921B1 (en) | 2003-06-17 | 2016-03-02 | Arena Pharmaceuticals, Inc. | 8-Chloro-1 -methyl-2,3,4,5-tetrahydro-1 H-3benzazapine Hydrochloride |
| CA2888392A1 (en) | 2003-06-17 | 2005-03-03 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
| WO2005042491A1 (en) | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| US20070275949A1 (en) | 2003-10-22 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases |
| AU2005268781A1 (en) | 2004-08-02 | 2006-02-09 | Genmedica Therapeutics Sl | Compounds for inhibiting copper-containing amine oxidases and uses thereof |
| US8178077B2 (en) | 2004-10-19 | 2012-05-15 | Reverse Proteomics Research Institute Co., Ltd. | Drug development target protein and target gene, and method of screening |
| EA201200954A1 (ru) | 2004-12-21 | 2013-05-30 | Арена Фармасьютикалз, Инк. | Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение |
| RS50997B (sr) | 2004-12-23 | 2010-10-31 | Arena Pharmaceuticals Inc. | Kompozicije 5ht2c receptor modulatora i postupci njihove upotrebe |
| EP2001852A2 (en) | 2006-04-03 | 2008-12-17 | Arena Pharmaceuticals, Inc. | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine and intermediates related thereto |
-
2003
- 2003-04-10 US US10/410,991 patent/US6953787B2/en not_active Expired - Lifetime
- 2003-04-11 KR KR1020087000551A patent/KR100908166B1/ko not_active Expired - Lifetime
- 2003-04-11 EP EP05002866A patent/EP1557409A1/en not_active Withdrawn
- 2003-04-11 NZ NZ535381A patent/NZ535381A/en not_active IP Right Cessation
- 2003-04-11 TW TW092108353A patent/TWI252105B/zh not_active IP Right Cessation
- 2003-04-11 PL PL373464A patent/PL211314B1/pl unknown
- 2003-04-11 ES ES03718323T patent/ES2242165T3/es not_active Expired - Lifetime
- 2003-04-11 ES ES10010297.9T patent/ES2670568T3/es not_active Expired - Lifetime
- 2003-04-11 KR KR1020047016198A patent/KR100812925B1/ko not_active Expired - Lifetime
- 2003-04-11 CN CNB038082721A patent/CN100486967C/zh not_active Expired - Lifetime
- 2003-04-11 CA CA002481723A patent/CA2481723C/en not_active Expired - Lifetime
- 2003-04-11 RU RU2004133068/04A patent/RU2317982C2/ru active
- 2003-04-11 PL PL396873A patent/PL231405B1/pl unknown
- 2003-04-11 BR BR122017023795A patent/BR122017023795B8/pt not_active IP Right Cessation
- 2003-04-11 IL IL16416203A patent/IL164162A0/xx unknown
- 2003-04-11 PL PL391780A patent/PL211333B1/pl unknown
- 2003-04-11 EP EP10010296A patent/EP2363394A1/en not_active Withdrawn
- 2003-04-11 PL PL391779A patent/PL219017B1/pl unknown
- 2003-04-11 AT AT03718323T patent/ATE294781T1/de active
- 2003-04-11 JP JP2003583332A patent/JP4155926B2/ja not_active Expired - Lifetime
- 2003-04-11 DE DE60300610T patent/DE60300610T2/de not_active Expired - Lifetime
- 2003-04-11 EP EP10010297.9A patent/EP2374796B1/en not_active Expired - Lifetime
- 2003-04-11 EP EP03718323A patent/EP1411881B9/en not_active Expired - Lifetime
- 2003-04-11 MY MYPI20031375A patent/MY141476A/en unknown
- 2003-04-11 PT PT03718323T patent/PT1411881E/pt unknown
- 2003-04-11 CN CNA2009100001925A patent/CN101486679A/zh active Pending
- 2003-04-11 BR BRPI0309303A patent/BRPI0309303B8/pt not_active IP Right Cessation
- 2003-04-11 WO PCT/US2003/011076 patent/WO2003086306A2/en not_active Ceased
- 2003-04-11 MX MXPA04009965A patent/MXPA04009965A/es active IP Right Grant
- 2003-04-11 AU AU2003221866A patent/AU2003221866B2/en not_active Expired
- 2003-04-11 KR KR1020097000060A patent/KR100908167B1/ko not_active Expired - Lifetime
- 2003-04-11 DK DK03718323T patent/DK1411881T3/da active
- 2003-04-11 CN CN2009100001906A patent/CN101486677B/zh not_active Expired - Lifetime
- 2003-04-11 SI SI200330049T patent/SI1411881T1/xx unknown
- 2003-04-11 CN CN200910000191.0A patent/CN101486678B/zh not_active Expired - Lifetime
- 2003-04-11 CN CNA200910000193XA patent/CN101485664A/zh not_active Withdrawn
- 2003-11-04 UA UA20041109253A patent/UA77788C2/uk unknown
-
2004
- 2004-08-13 US US10/917,979 patent/US7514422B2/en not_active Expired - Lifetime
- 2004-09-28 CR CR7503A patent/CR7503A/es unknown
- 2004-10-06 IS IS7490A patent/IS2134B/xx unknown
- 2004-10-20 ZA ZA200408506A patent/ZA200408506B/en unknown
- 2004-11-11 NO NO20044928A patent/NO323528B1/no not_active IP Right Cessation
-
2006
- 2006-03-03 JP JP2006058747A patent/JP4191741B2/ja not_active Expired - Lifetime
- 2006-11-14 US US11/599,050 patent/US7977329B2/en not_active Expired - Fee Related
-
2007
- 2007-02-15 GE GEAP20079867A patent/GEP20074197B/en unknown
-
2008
- 2008-08-05 JP JP2008202412A patent/JP4966929B2/ja not_active Expired - Lifetime
- 2008-10-22 CR CR10393A patent/CR10393A/es not_active Application Discontinuation
-
2011
- 2011-05-27 US US13/118,126 patent/US8207158B2/en not_active Expired - Fee Related
- 2011-09-14 JP JP2011201117A patent/JP5602116B2/ja not_active Expired - Lifetime
-
2012
- 2012-06-14 US US13/523,805 patent/US8273734B1/en not_active Expired - Fee Related
- 2012-09-14 US US13/617,072 patent/US8546379B2/en not_active Expired - Fee Related
- 2012-09-14 US US13/616,981 patent/US8846906B2/en not_active Expired - Lifetime
- 2012-09-14 US US13/620,204 patent/US8575149B2/en not_active Expired - Fee Related
- 2012-09-25 JP JP2012211059A patent/JP2013018780A/ja not_active Withdrawn
-
2014
- 2014-07-09 US US14/326,977 patent/US8993750B2/en not_active Expired - Lifetime
-
2015
- 2015-02-23 US US14/629,083 patent/US20160024014A1/en not_active Abandoned
-
2016
- 2016-05-12 US US15/152,648 patent/US20160250223A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323528B1 (no) | 5HT2C reseptormodulatorer, farmasoytiske preparater omfattende disse samt anvendelse derav. | |
| HK1162486A (en) | 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of cns disorders | |
| HK1064095B (en) | 5ht2c receptor modulators | |
| HK1161597A (en) | 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of cns disorders | |
| HK1162486B (en) | 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |